دورية أكاديمية
Downstaging with Atezolizumab-Bevacizumab: A Case Series.
| العنوان: | Downstaging with Atezolizumab-Bevacizumab: A Case Series. |
|---|---|
| المؤلفون: | Kulkarni AV; Department of Hepatology, AIG Hospitals, Hyderabad, India., P K; Department of Liver Transplant Surgery, AIG Hospitals, Hyderabad, India., Menon B; Department of Liver Transplant Surgery, AIG Hospitals, Hyderabad, India., Sekaran A; Department of Pathology, AIG Hospitals, Hyderabad, India., Rambhatl A; Department of Liver Transplant Anaesthesia, AIG Hospitals, Hyderabad, India., Iyengar S; Department of Hepatology, AIG Hospitals, Hyderabad, India., Alla M; Department of Hepatology, AIG Hospitals, Hyderabad, India., Venishetty S; Department of Hepatology, AIG Hospitals, Hyderabad, India., Ramachandra SK; Department of Liver Transplant Surgery, AIG Hospitals, Hyderabad, India., V PG; Department of Liver Transplant Anaesthesia, AIG Hospitals, Hyderabad, India., Sharma M; Department of Hepatology, AIG Hospitals, Hyderabad, India., Rao PN; Department of Hepatology, AIG Hospitals, Hyderabad, India., Reddy DN; Department of Hepatology, AIG Hospitals, Hyderabad, India., Singal AG; Department of Medicine, UT Southwestern Medical Centre, Dallas, Texas, USA. |
| المصدر: | Journal of liver cancer [J Liver Cancer] 2024 May 27. Date of Electronic Publication: 2024 May 27. |
| Publication Model: | Ahead of Print |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Korean Liver Cancer Association Country of Publication: Korea (South) NLM ID: 101650610 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2383-5001 (Electronic) Linking ISSN: 22888128 NLM ISO Abbreviation: J Liver Cancer |
| أسماء مطبوعة: | Original Publication: S̆oul T'ŭkpyŏlsi, Kangnam-gu : Korean Liver Cancer Association, [2014]- |
| مستخلص: | Background/aims: Hepatocellular carcinoma (HCC) is generally diagnosed at an advanced stage, which limits curative treatment options for these patients. Locoregional therapy (LRT) is the standard approach to bridge and downstage unresectable HCC (uHCC) for liver transplantation (LT). Atezolizumab-bevacizumab (atezo-bev) can induce objective responses in nearly one-third of patients; however, the role and outcomes of downstaging using atezobev remains unknown. Methods: In this retrospective single-center study, we included consecutive patients between November 2020 and August 2023, who received atezo-bev with or without LRT and were subsequently considered for resection/LT after downstaging. Results: Of the 115 patients who received atezo-bev, 12 patients (10.4%) achieved complete or partial response and were willing to undergo LT; they (age: 58.5 years; women-17%; Barcelona Clinic Liver Cancer Stage System B/C:5/7) had received 3-12 cycles of atezo-bev, and 4 of them had received prior LRT. Three patients died before LT, while three were awaiting LT. Six patients underwent curative therapies: four underwent living donor LT after a median of 79.5 (54-114) days following the last atezo-bev dose, one underwent deceased donor LT 38 days after the last dose, and one underwent resection. All but one patient had complete pathologic response with no viable HCC. Three patients experienced wound healing complications, and one required re-exploration and succumbed to sepsis. After a median follow-up of 10 (4-30) months, none of the alive patients developed HCC recurrence or graft rejection. Conclusions: Surgical therapy, including LT, is possible after atezo-bev therapy in wellselected patients after downstaging. |
| فهرسة مساهمة: | Keywords: Hepatocellular carcinoma; downstaging; immunotherapy; liquid biopsy |
| تواريخ الأحداث: | Date Created: 20240527 Latest Revision: 20240527 |
| رمز التحديث: | 20240527 |
| DOI: | 10.17998/jlc.2024.05.12 |
| PMID: | 38797993 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2383-5001 |
|---|---|
| DOI: | 10.17998/jlc.2024.05.12 |